An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

Amgen's study of the drug Maritide in people with Type 2 diabetes showed noteworthy reductions in HbA1c and weight. The ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Thousand Oaks-based Amgen Inc. on Jan. 6 announced it has acquired Oxford, U.K.-based Dark Blue Therapeutics Ltd., a ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...